ALK201

· Shanghai Allink Biotherapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALK201, covering 2026-03-06 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

See pricing